Loading company…
Stipple Bio develops precision oncology medicines based on mapping tumor-specific epitopes.
Stipple Bio researches precision cancer medicines by identifying and mapping tumor-specific epitopes. It serves healthcare providers and research institutions developing targeted cancer therapies. Founded in 2022, the company is based in Cambridge, US. In March 2026, it raised USD 65.13 mn in Series A funding co-led by RA Capital Management, Nextech, and Andreessen Horowitz.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in